At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
ChAdOx1-HBV +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of VTP-300 With or Without Nivolumab in Participants With Chronic Hepatitis B Infection
In Brief
A Phase 2 clinical trial evaluating ChAdOx1-HBV, MVA-HBV, and 1 other intervention for Hepatitis B. Completed, enrolled 55 participants across 12 sites in 3 countries.
Detailed Summary
This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesSouth Korea, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedMar 2021
Primary CompletionFeb 2023
TodayJul 2026
First PostedMar 3, 2021
Enrollment StartDec 22, 2020
Primary CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.3 years ago
Interventions
ChAdOx1-HBVbiological
Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
MVA-HBVbiological
Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
Nivolumabbiological
Human immunoglobulin G4 monoclonal antibody